Overview

* Olema reports Q3 net loss of $42.2 mln due to increased R&D expenses

* Company ends Q3 with $329 mln in cash and marketable securities

* Announced clinical trial agreement with Pfizer for palazestrant and atirmociclib

Outlook

* Company to initiate Phase 1b/2 study with Pfizer in Q4 2025

* Olema to present trial poster at SABCS in December 2025

Result Drivers

* CLINICAL TRIAL AGREEMENT - Announced agreement with Pfizer to evaluate palazestrant with atirmociclib in ER+/HER2- metastatic breast cancer

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$42.22

Income mln

Q3 -$45.88

Income mln

From

Operatio

ns

Q3 $45.88

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Olema Pharmaceuticals Inc ( OLMA ) is $22.00, about 62% above its November 7 closing price of $8.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)